About 7-OH: Understanding This Powerful Kratom Alkaloid

Abstract

7-Hydroxymitragynine (7-OH) is a minor yet significant alkaloid derived from Mitragyna Speciosa. Although it occurs in trace amounts, it binds with opioid receptors, especially with μ-opioid receptors, and has drawn scientific attention. 7-OH has been studied for its analgesic properties, receptor binding affinity, and potential risks, especially when synthetically concentrated in commercial extracts.

This paper reviews its biosynthesis, pharmacological activity, safety concerns, and legal status, highlighting the major research gap that limits our current understanding of its full profile.

Keywords: 7-hydroxymitragynine, kratom alkaloid, opioid receptor, 7-OH legality, mitragynine, pharmacology of 7-OH

Introduction

7-OH is an indole-based alkaloid naturally found in the leaves of Mitragyna Speciosa, commonly known as Kratom. Although it exists in only trace concentrations in unprocessed Kratom leaf matter, typically less than 0.02% by weight, it plays an important role in discussions related to the plant’s pharmacological impact and regulatory challenges. Of particular interest is 7-OH’s high binding affinity for μ-opioid receptors, which has positioned it as a potent compound in both scientific literature and public debate. Unlike mitragynine, the more abundant Kratom alkaloid, 7-OH exhibits greater potency in preclinical models and has been studied for its analgesic potential and opioid-like properties.

Its role in enhanced Kratom extracts—where it may be synthetically concentrated—has raised questions about safety, abuse potential, and legality. This review explores its biosynthetic origin, its pharmacological behavior, safety profile, and legal classification, while identifying key gaps in current knowledge that warrant further investigation.

Origin & Biosythesis

7-Hydroxymitragynine (7-OH) is a secondary metabolite derived from Mitragyna speciosa, where it occurs in only trace quantities, typically below 0.02% of the total alkaloid profile. Despite its low natural abundance, its formation through metabolic or chemical pathways significantly elevates its pharmacological relevance.

Biogenically, 7-OH is generated through metabolic oxidation of mitragynine in mammalian systems. Studies involving liver microsomal assays have confirmed that cytochrome P450 enzymes, particularly CYP3A4, catalyze the conversion of mitragynine into 7-Hydroxymitragynine in both human and rodent models. This oxidative transformation has been associated with an increase in opioid receptor affinity observed after mitragynine administration, suggesting that the in vivo activity of Kratom may partly depend on 7-OH as an active metabolite.

From a structural standpoint, 7-OH retains the indole core of mitragynine but features a hydroxyl functional group at the C7 position.

Safety

Despite its potent pharmacological activity, the safety profile of 7-Hydroxymitragynine in humans remains largely undefined. Most available data are derived from animal studies and in vitro analyses. In early rodent models, 7-OH was shown to produce strong antinociceptive effects.

More recent investigations have examined the potential for opioid-like adverse effects. A 2022 study using plethysmography in mice demonstrated that 7-OH induces dose-dependent respiratory depression, with reductions in minute ventilation, breathing frequency, and tidal volume, comparable to morphine. This effect was not observed with mitragynine alone unless it was metabolized to 7-OH, reinforcing the central role of this metabolite in mediating opioid toxicity.

Legality

At the federal level, neither mitragynine nor 7-Hydroxymitragynine is currently listed in the Controlled Substances Act, meaning it remains unscheduled federally.

At the state level, regulations vary considerably. Several states have classified mitragynine and 7‑OH as Schedule I controlled substances, making them illegal: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin have enacted such bans. 

Other states regulate 7‑OH indirectly through the Kratom Consumer Protection Act (KCPA), which places limits on its concentration, typically to 2% or less of total alkaloids (e.g., Arizona, Colorado, Nevada, Oklahoma, Utah).

Some states have partial bans tied to specific cities or regions (e.g., Denver, CO; Miami-Dade, FL; San Diego, CA), or age-based restrictions (e.g., Florida and New York require purchasers to be 21 or older).

Research Gaps

Despite promising pharmacological findings, significant gaps remain in the understanding of 7-Hydroxymitragynine. No clinical trials have evaluated its dose–response, long-term safety, or tolerance in humans. Variability in CYP3A4 activity suggests individual differences in 7-OH formation, but human pharmacokinetic data are lacking. Additionally, the presence of concentrated 7-OH in commercial Kratom extracts raises concerns due to the absence of standardized potency limits and labeling practices. Lastly, while animal studies suggest abuse potential, no human studies have assessed its dependence liability or withdrawal profile. Targeted research is essential to clarify these unknowns.

References:

1. Takayama, H. (2004). Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chemical & Pharmaceutical Bulletin, 52(8), 916–928.

https://www.jstage.jst.go.jp/article/cpb/52/8/52_8_916/_article

2. Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M. R., Le Rouzic, V., ... & Majumdar, S. (2016). Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2. Journal of Medicinal Chemistry, 59(18), 8381–8397.

https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00748

3. Spetea, M., & Schmidhammer, H. (2019). Unveiling 7-hydroxymitragynine as the key active metabolite of mitragynine and the promise for creating novel pain relievers. Frontiers in Pharmacology, 10, 869.

https://pmc.ncbi.nlm.nih.gov/articles/PMC6598155/

4. Eastlack, S. C., Cornett, E. M., & Kaye, A. D. (2020). Kratom—Pharmacology, clinical implications, and outlook: A comprehensive review. Pain and Therapy, 9(1), 55–69.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7203303/

5. Mongar, P., Jaisi, A., Inkviya, T., Wungsintaweekul, J., & Wiwattanawongsa, K. (2023). Effects of itraconazole on pharmacokinetics of mitragynine and 7‑hydroxymitragynine in healthy volunteers. Journal of Clinical Pharmacology and Experimental Therapeutics, 12(3), 145–157.

https://pubmed.ncbi.nlm.nih.gov/38481700/

6. Kruegel, A. C., & Grundmann, O. (2018). The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology, 134(Pt A), 108–120.

https://www.sciencedirect.com/science/article/abs/pii/S0028390817303933?via%3Dihub

7. Matsumoto, K., Horie, S., Ishikawa, H., Takayama, H., Aimi, N., Ponglux, D., & Watanabe, K. (2004). Antinociceptive effect of 7‑hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sciences, 74(17), 2143–2155.

https://www.sciencedirect.com/science/article/abs/pii/S0024320503011664

8. Hill, R., Kruegel, A. C., Javitch, J. A., Lane, J. R., & Canals, M. (2022). The respiratory depressant effects of mitragynine are limited by its conversion to 7‑OH mitragynine. British Journal of Pharmacology, 179(14), 3875–3885

https://pmc.ncbi.nlm.nih.gov/articles/PMC9314834/

9. U.S. Congress. (2023). S.3039 – Federal Kratom Consumer Protection Act of 2023 (118th Cong.).

https://www.congress.gov/bill/118th-congress/senate-bill/3039